TEVA-PIRFENIDONE 267 MG — DIN 02497689
PIRFENIDONE : 267 MG · TEVA CANADA LIMITED · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is TEVA-PIRFENIDONE?
TEVA-PIRFENIDONE 267 MG contains PIRFENIDONE : 267 MG. It is listed in the Health Canada Drug Product Database under DIN 02497689, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 30-Jul-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
How much does Pirfenidone cost around the world?
Pirfenidone is listed on 13 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| United States | acquisition | 2 | 38 |
| Italy | ex-factory (classe H) | 12 | 24 |
| Czechia | max producer price (ex-factory) | 5 | 15 |
| Greece | producer price (ex-factory) | 14 | 14 |
| Australia | ex-manufacturer | 5 | 10 |
| Saudi Arabia | public | 7 | 9 |
| Austria | KVP (Kassenverkaufspreis) | 6 | 6 |
| Luxembourg | reimbursement | 4 | 4 |
| South Africa | single exit price | 4 | 4 |
| United Kingdom | hospital | 3 | 3 |
| United Arab Emirates | public | 2 | 2 |
| Bahrain | retail (max) | 1 | 2 |
| Hungary | producer price (ex-factory) | 2 | 2 |
133 pack listings across 67 brand entries and 11 price bases, refreshed 10 Sep 2026. Ranges span every Pirfenidone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Pirfenidone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Pirfenidone, across 19 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 3 | 3 | JAMP PIRFENIDONE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | SANDOZ PIRFENIDONE CAPSULES, SANDOZ PIRFENIDONE TABLETS | Sourceable in Canada |
| HOFFMANN-LA ROCHE LIMITED | 3 | 2 | ESBRIET | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-PIRFENIDONE | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-PIRFENIDONE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 2 | 0 | MAR-PIRFENIDONE | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-PIRFENIDONE | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | TEVA-PIRFENIDONE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 267 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Pirfenidone |
|---|---|
| ATC code | L04AX05 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02497689 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2497689 |
| Brand name | TEVA-PIRFENIDONE |
| Generic / active ingredient | PIRFENIDONE : 267 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L04AX05 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AX |
| Current status | CANCELLED PRE MARKET |
| Status date | 30-Jul-2026 |
| Original market date | 2021-07-13 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-PIRFENIDONE | 801 MG | TABLET | AURO PHARMA INC | MARKETED | 02537761 |
| AURO-PIRFENIDONE | 267 MG | TABLET | AURO PHARMA INC | MARKETED | 02537753 |
| ESBRIET | 801 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02464500 |
| ESBRIET | 267 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | MARKETED | 02464489 |
| JAMP PIRFENIDONE | 267 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | 02509938 |
| JAMP PIRFENIDONE | 267 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02514702 |
| JAMP PIRFENIDONE | 801 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02514710 |
| M-PIRFENIDONE | 801 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02550652 |
| M-PIRFENIDONE | 267 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02550644 |
| SANDOZ PIRFENIDONE CAPSULES | 267 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | 02488833 |
2 · Same class — other molecules in ATC L04AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lenalidomide | APO-LENALIDOMIDE · EUGIA-LENALIDOMIDE · JAMP LENALIDOMIDE · LENALIDOMIDE · +6 more | 62 | 42 | Yes |
| Methotrexate | AURO-METHOTREXATE · METHOFILL SELF-DOSE INJECTOR · METHOTREXATE SUBCUTANEOUS · METOJECT SUBCUTANEOUS · +3 more | 41 | 29 | Yes |
| Pomalidomide | APO-POMALIDOMIDE · JAMP POMALIDOMIDE · NAT-POMALIDOMIDE · POMALIDOMIDE · +3 more | 28 | 24 | Yes |
| Dimethyl Fumarate | ACH-DIMETHYL FUMARATE · APO-DIMETHYL FUMARATE · AURO-DIMETHYL FUMARATE · GLN-DIMETHYL FUMARATE · +7 more | 22 | 12 | Yes |
| Pirfenidone | AURO-PIRFENIDONE · ESBRIET · JAMP PIRFENIDONE · M-PIRFENIDONE · +5 more | 19 | 12 | Yes |
| Azathioprine | APO-AZATHIOPRINE · AZATHIOPRINE · AZATHIOPRINE SODIUM FOR INJECTION · AZATHIOPRINE-50 · +8 more | 14 | 3 | Yes |
| Thalidomide | THALOMID | 4 | 2 | Yes |
| Other Immunosuppressants | PROCHYMAL | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AC | Anakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more | 85 | 75 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-PIRFENIDONE called?
The same molecule, Pirfenidone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Esbriet | Latin | Bahrain, Czechia, South Africa |
| FREDALIX | Latin | Czechia |
| PIRFENIDON ZENTIVA | Latin | Czechia |
| PIRFENIDONE ACCORD | Latin | Czechia |
| PIRFENIDONE TEVA | Latin | Czechia |
| ARX-Pirfenidone | Latin | Australia |
| Donfer | Latin | Saudi Arabia |
| Fenido | Latin | Saudi Arabia |
| Pirfenidet | Latin | Australia |
| Pirfenidone Ameda | Latin | Australia |
| Pirfenidone Dr.Reddy's | Latin | Australia |
| Pirfenidone Sandoz | Latin | Australia |
| PIRDONE | Latin | Saudi Arabia |
| Pirfenidone Actavis | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Pirfenidone called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Pirfenidone, published to help those searches reach this page.
| Language | Pirfenidone |
|---|---|
| Arabic العربية | بيرفينيدون |
| Chinese (Simplified) 简体中文 | 吡非尼酮 |
| Russian Русский | Пирфенидон |
| Spanish Español | Pirfenidona |
| French Français | Pirfénidone |
| Portuguese Português | Pirfenidona |
| German Deutsch | Pirfenidon |
| Japanese 日本語 | ピルフェニドン |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.